Drug name - Ocaliva

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7138390 INTERCEPT PHARMS INC Steroids as agonists for FXR
Nov, 2022

(a month from now)

USRE48286 INTERCEPT PHARMS INC Steroids as agonists for FXR
Feb, 2027

(4 years from now)

US10174073 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Jun, 2033

(10 years from now)

CN104781272A INTERCEPT PHARMS INC Preparation, Application And Solid Form Of Obeticholic Acid
Sep, 2020

(2 years ago)

CN108495858A INTERCEPT PHARMS INC Poly-Crystalline Form Austenitic-Bainite
Jan, 2021

(1 year, 8 months ago)

EP1392714B1 INTERCEPT PHARMS INC Steroids As Agonists For Fxr
Feb, 2022

(7 months ago)

EP1392714A1 INTERCEPT PHARMS INC Steroids As Agonists For Fxr
Feb, 2022

(7 months ago)

EP3336097A1 INTERCEPT PHARMS INC Preparation Of The Non-Crystalline Form Of Obeticholic Acid
Jun, 2033

(10 years from now)

EP3336097B1 INTERCEPT PHARMS INC Preparation Of The Non-Crystalline Form Of Obeticholic Acid
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238673 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid Jun, 2033

(10 years from now)

US10047117 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid Sep, 2033

(10 years from now)

US10052337 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use Apr, 2036

(13 years from now)

US10758549 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use Apr, 2036

(13 years from now)

US10751349 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use Apr, 2036

(13 years from now)

Drugs and Companies using OBETICHOLIC ACID ingredient

Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.